The NanoVelcro CTC-RNA assay: a new method for contemporary genomics and precision medicine via liquid biopsy

Edwin M Posadas1,3,4, Pai-Chi Teng1,4, Yu-Jen Jan1,4, Jie-Fu Chen1,4, Minhyung Kim5, Nu Yao3,4, Isla Garraway8, Gina Chu2,3,4, Howard Chung7, Pin-Jung Chen7, Jasmine Wang3,4, Yi-Ti Lee7, Yazhen Zhu7, Beatrice Knudsen1,3, Leland WK Chung2,3,4, Sungyong Yous5, Michael R Freeman2,5, Hsian-Rong Tseng2

1Translational Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA
2Cancer Biology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA
3Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA
4Division of Solid Tumor Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA
5Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA
6Department of Radiation Oncology, University of California- San Francisco, San Francisco, CA
7Department of Molecular and Molecular Pharmacology, University of California- Los Angeles, Los Angeles, CA
8Division of Urology, Department of Surgery, Greater Los Angeles Veteran Affairs Medical Center, Los Angeles, CA

Background: Genome and transcriptome-based analysis has begun to reshape the approach to prostate cancer. Two different gene expression signatures have shown that prostate cancers can be divided into 3 subclasses reflecting luminal basal biology. These subtypes point toward biological drivers that may strongly influence how care should be personalized including optimization of androgen receptor targeted therapy. The majority of work done in this area has been based on tissue-based gene expression. With the advent of newer nanotechnology platforms for isolation of circulating tumor cells (CTCs), profiling of gene expression from blood is now possible.

Methods: We combined variations of the NanoVelcro assay (thermoreponsive, click-chemistry) allowing for capture and release of CTCs with intact RNA. Gene sets from the PCS and PAM50 signatures were reviewed to optimize signal detection in the blood and enrich for genes upregulated in prostate cancer. An nCounter NanoString assay was developed to include the resulting genes. A pilot study was conducted using banked samples available through the Urologic Oncology Program Blood and Biospecimen Bank.

Results: The final assay was tested in banked blood samples and provided classifications of patients that associated with clinical responsiveness to therapy. In particular, during emergence of resistance, we see an increase in expression of genes related to the PCS1/Basal phenotypes.

Conclusions: This study shows initial proof of principle that genomic classification in blood is possible using contemporary tool for blood component isolation and nanostring. Additional technical and clinical validation are needed prior to widespread implementation, but these methods may make it possible to increase the utilization of genomic classifiers in clinical studies and in practice.

Funding: NCI SP01CA098912, R01CA218356, U01CA198900; DOD PCRP W81XWH-16-1-0638, W81XWH-18-1-0576, W81XWH-19-1-0392, St. Anthony Discovery Fund for Prostate Cancer Research, C Dan McKinnon Memorial Fund for Neuroendocrine Prostate Cancers, Michael & Patricia Berns Family Fund for Prostate Cancer Research.